Anticoagulant Safety Remains a Problem
Emergency Hospitalizations for Adverse Drug Events
Comparative Pharmacology
Inducers and Inhibitors of Cytochrome P450 3A4 and P-gp
Novel Anticoagulants for Stroke Prevention in AF
Trials With NOACs vs Warfarin in AF
All NOACs and Stroke or SE Event
ENGAGE AF-TIMI 48: Primary End Point Stroke/Systemic Embolic Event (2.8-y median
follow-up)
ENGAGE AF-TIMI 48 Bleeding
Who Should Remain on Warfarin?
EINSTEIN DVT/PEStudy Designs
Switching From Warfarin to NOACs
Adverse Events
SummaryBenefits of NOACs
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
Top Related